These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 36910721)

  • 61. Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin.
    Arabi L; Badiee A; Mosaffa F; Jaafari MR
    J Control Release; 2015 Dec; 220(Pt A):275-286. PubMed ID: 26518722
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model.
    Zahmatkeshan M; Gheybi F; Rezayat SM; Jaafari MR
    Eur J Pharm Sci; 2016 Apr; 86():125-35. PubMed ID: 26972276
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Chemotherapeutic drug delivery to cancer cells using a combination of folate targeting and tumor microenvironment-sensitive polypeptides.
    Gao W; Xiang B; Meng TT; Liu F; Qi XR
    Biomaterials; 2013 May; 34(16):4137-4149. PubMed ID: 23453200
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Dual drug loaded liposome bearing apigenin and 5-Fluorouracil for synergistic therapeutic efficacy in colorectal cancer.
    Sen K; Banerjee S; Mandal M
    Colloids Surf B Biointerfaces; 2019 Aug; 180():9-22. PubMed ID: 31015105
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Tumor-targeted paclitaxel delivery and enhanced penetration using TAT-decorated liposomes comprising redox-responsive poly(ethylene glycol).
    Fu H; Shi K; Hu G; Yang Y; Kuang Q; Lu L; Zhang L; Chen W; Dong M; Chen Y; He Q
    J Pharm Sci; 2015 Mar; 104(3):1160-73. PubMed ID: 25449709
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A tumor vasculature targeted liposome delivery system for combretastatin A4: design, characterization, and in vitro evaluation.
    Nallamothu R; Wood GC; Pattillo CB; Scott RC; Kiani MF; Moore BM; Thoma LA
    AAPS PharmSciTech; 2006 Apr; 7(2):E32. PubMed ID: 16796350
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Tumor targeting using anti-her2 immunoliposomes.
    Park JW; Kirpotin DB; Hong K; Shalaby R; Shao Y; Nielsen UB; Marks JD; Papahadjopoulos D; Benz CC
    J Control Release; 2001 Jul; 74(1-3):95-113. PubMed ID: 11489487
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A study on the role of cholesterol and phosphatidylcholine in various features of liposomal doxorubicin: From liposomal preparation to therapy.
    Farzaneh H; Ebrahimi Nik M; Mashreghi M; Saberi Z; Jaafari MR; Teymouri M
    Int J Pharm; 2018 Nov; 551(1-2):300-308. PubMed ID: 30243944
    [TBL] [Abstract][Full Text] [Related]  

  • 69. PEGylated phospholipid micelles containing D-α-tocopheryl succinate as multifunctional nanocarriers for enhancing the antitumor efficacy of doxorubicin.
    Jiang W; Fan Q; Wang J; Zhang B; Hao T; Chen Q; Li L; Chen L; Cui H; Li Z
    Int J Pharm; 2021 Sep; 607():120979. PubMed ID: 34371151
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Co-Delivery of Hispolon and Doxorubicin Liposomes Improves Efficacy Against Melanoma Cells.
    Al Saqr A; Aldawsari MF; Alrbyawi H; Poudel I; Annaji M; Mulabagal V; Ramani MV; Gottumukkala S; Tiwari AK; Dhanasekaran M; Panizzi PR; Arnold RD; Babu RJ
    AAPS PharmSciTech; 2020 Nov; 21(8):304. PubMed ID: 33150503
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Investigating the Fate of MP1000-LPX
    He S; Xia S; Song X; Huang H; Wang X; Jiang X; Jin Z
    Pharm Nanotechnol; 2020; 8(5):399-408. PubMed ID: 32895048
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Reduction-triggered delivery using nucleoside-lipid based carriers possessing a cleavable PEG coating.
    Oumzil K; Khiati S; Grinstaff MW; Barthélémy P
    J Control Release; 2011 Apr; 151(2):123-30. PubMed ID: 21354443
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comparative study of the in vitro and in vivo characteristics of cationic and neutral liposomes.
    Zhao W; Zhuang S; Qi XR
    Int J Nanomedicine; 2011; 6():3087-98. PubMed ID: 22163162
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Tumor microenvironment-activated cancer cell membrane-liposome hybrid nanoparticle-mediated synergistic metabolic therapy and chemotherapy for non-small cell lung cancer.
    Zhang W; Gong C; Chen Z; Li M; Li Y; Gao J
    J Nanobiotechnology; 2021 Oct; 19(1):339. PubMed ID: 34689761
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Increased delivery of doxorubicin into tumor cells using extracellularly activated TAT functionalized liposomes: in vitro and in vivo study.
    Yuan W; Kuai R; Ran R; Fu L; Yang Y; Qin Y; Liu Y; Tang J; Fu H; Zhang Q; Yuan M; Zhang Z; Gao F; He Q
    J Biomed Nanotechnol; 2014 Aug; 10(8):1563-73. PubMed ID: 25016656
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Increased tumor targeted delivery using a multistage liposome system functionalized with RGD, TAT and cleavable PEG.
    Mei L; Fu L; Shi K; Zhang Q; Liu Y; Tang J; Gao H; Zhang Z; He Q
    Int J Pharm; 2014 Jul; 468(1-2):26-38. PubMed ID: 24709209
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
    Moosavian SA; Abnous K; Badiee A; Jaafari MR
    Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Dual functional matrix metalloproteinase-responsive curcumin-loaded nanoparticles for tumor-targeted treatment.
    Guo F; Fu Q; Jin C; Ji X; Yan Q; Yang Q; Wu D; Gao Y; Hong W; Li A; Yang G
    Drug Deliv; 2019 Dec; 26(1):1027-1038. PubMed ID: 31691601
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Peritumoral implantation of hydrogel-containing nanoparticles and losartan for enhanced nanoparticle penetration and antitumor effect.
    Shen H; Gao Q; Ye Q; Yang S; Wu Y; Huang Q; Wang X; Sun Z
    Int J Nanomedicine; 2018; 13():7409-7426. PubMed ID: 30519023
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Engineering of Bone- and CD44-Dual-Targeting Redox-Sensitive Liposomes for the Treatment of Orthotopic Osteosarcoma.
    Feng S; Wu ZX; Zhao Z; Liu J; Sun K; Guo C; Wang H; Wu Z
    ACS Appl Mater Interfaces; 2019 Feb; 11(7):7357-7368. PubMed ID: 30682240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.